Processa Pharmaceuticals (PCSA) Change in Receivables (2012 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly Change in Receivables came in at -$25000.0 in Q1 2016, up 71.0% YoY from -$14619.7 in Q2 2015, and down 2008.4% on a QoQ basis from $1310.0 in Q4 2015.
Processa Pharmaceuticals (PCSA) Change in Receivables (2012 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 5 years of Change in Receivables data on file, last reported at -$25000.0 in Q1 2016.
- Quarterly Change in Receivables rose 71.0% year-over-year to -$25000.0 in Q1 2016, while the trailing twelve-month figure through Jun 2016 was $59925.0 (up 569.03% YoY) and the FY2015 annual result came in at -$3838.0, down 121.45% from the prior year.
- Change in Receivables declined to -$25000.0 in Q1 2016, from $1310.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $83615.0 in Q3 2015 to a low of -$86214.0 in Q1 2015.
- A 5-year average of $370.07 and a median of $1310.0 in 2015 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2014 — Change in Receivables surged 389.11% — and 2015, when it plunged 7429.61%.
- Tracing PCSA's Change in Receivables over 5 years: stood at -$30451.0 in 2012, then surged by 117.07% to $5199.0 in 2013, then surged by 389.11% to $25429.0 in 2014, then sank by 94.85% to $1310.0 in 2015, then tumbled by 2008.4% to -$25000.0 in 2016.
- The last three Change in Receivables figures came in at -$25000.0 (Q1 2016), $1310.0 (Q4 2015), and $83615.0 (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 31.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 37.16 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 94.29 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -25,000.00 |
| Mar 31, 2016 | -25,000.00 |
| Dec 31, 2015 | 1,310.00 |
| Dec 31, 2015 | 1,310.00 |
| Sep 30, 2015 | 83,615.00 |
| Sep 30, 2015 | 83,615.00 |
| Jun 30, 2015 | -2,549.00 |
| Jun 30, 2015 | -2,549.00 |
| Mar 31, 2015 | -86,214.00 |
| Mar 31, 2015 | -86,214.00 |
| Dec 31, 2014 | 25,429.00 |
| Dec 31, 2014 | 25,429.00 |
| Sep 30, 2014 | 72,291.00 |
| Sep 30, 2014 | 72,291.00 |
| Jun 30, 2014 | -78,685.00 |
| Jun 30, 2014 | -78,685.00 |
| Mar 31, 2014 | -1,145.00 |
| Mar 31, 2014 | -1,145.00 |
| Dec 31, 2013 | 5,199.00 |
| Dec 31, 2013 | 5,199.00 |